Share

    


In This Section

Home / Learn / Precision Medicine / Treatment / Bispecific Antibodies / Sharing Operational Insights for the Delivery of Bispecific Antibodies in Solid Tumors

Sharing Operational Insights for the Delivery of Bispecific Antibodies in Solid Tumors

Clinical data and research indicate that bispecific antibodies have significant immunotherapeutic potential and may soon become available to treat solid tumors. Exploring the potential of bispecific antibodies as treatment options for patients with small cell lung, prostate, gastrointestinal, and other cancers.

Building upon its important work in the bispecific antibodies space, the Association of Cancer Care Centers (ACCC) has developed an educational program to prepare care teams for the delivery of these treatments in community and rural cancer programs when they become available. This program explores the latest findings in solid tumor applications and best practices for the use of bispecific antibodies in cancer care.

For more information about this project, please contact the ACCC Provider Education Department.

This project is sponsored by Amgen; however, Amgen did not exert any editorial control on the content.

Featured Resources

Sharing Operational Insights for the Delivery of Bispecific Antibodies in Solid Tumors

Spotlight on West Virginia University Cancer Institute

West Virginia University (WVU) Cancer Institute has made notable strides in utilizing bispecific antibodies for innovative cancer treatments. This spotlight reviews WVU's best practices that help ensure their patients are able to receive advanced therapies despite logistical and socioeconomic challenges.
Read More

Cancer Buzz Podcasts

Navigating the Operational Challenges of Treatment with Bispecific Antibodies - [Podcast] Ep 148

Mar 28, 2024

Advancements in clinical data and research have shown the immunotherapeutic potential of bispecific antibodies as treatment for hematologic cancers and solid tumors. In this episode, CANCER BUZZ speaks with Aaron Cumpston, PharmD, pharmacy clinical specialist in hematologic malignancies and bone marrow transplant and Christine Barrett, PharmD, BCOP, medical oncology clinical pharmacy specialist at WVU Cancer Institute who discuss the challenges of care coordination and therapy and share operational best practices for the delivery of bispecific antibodies in the community settings

 

 

 

Our Supporter


Amgen Logo

This project is made possible by support from Amgen.